Hypertrophic Cardiomyopathy versus Storage Diseases with Myocardial Involvement
暂无分享,去创建一个
[1] B. Lewis,et al. 2023 ESC Guidelines for the management of cardiomyopathies. , 2023, European heart journal.
[2] Daoquan Peng,et al. Identification of a novel splicing‐altering LAMP2 variant in a Chinese family with Danon disease , 2023, ESC heart failure.
[3] E. Brusse,et al. Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective study , 2023, Orphanet Journal of Rare Diseases.
[4] Christopher A. Miller,et al. Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy , 2023, Heart.
[5] Y. Chien,et al. Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks , 2023, JAMA neurology.
[6] E. Boersma,et al. Effects of enzyme replacement therapy on cardiac function in classic infantile Pompe disease. , 2023, International journal of cardiology.
[7] Zheng Wen,et al. Homology-directed repair of an MYBPC3 gene mutation in a rat model of hypertrophic cardiomyopathy , 2023, Gene Therapy.
[8] B. Maranda,et al. Mass Spectrometry Analysis of Globotriaosylsphingosine and Its Analogues in Dried Blood Spots , 2023, International journal of molecular sciences.
[9] E. Olson,et al. Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice , 2023, Nature Medicine.
[10] D. Bali,et al. Phase I Study of Liver Depot Gene Therapy in Late-onset Pompe Disease. , 2023, Molecular therapy : the journal of the American Society of Gene Therapy.
[11] F. Pieruzzi,et al. Effect of Migalastat on cArdiac InvOlvement in FabRry DiseAse: MAIORA study , 2023, Journal of Medical Genetics.
[12] M. Wheeler,et al. Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption , 2023, JAMA cardiology.
[13] Rose M. Sheridan,et al. Preclinical evaluation of FLT190, a liver-directed AAV gene therapy for Fabry disease , 2023, Gene Therapy.
[14] C. Kramer,et al. Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy. , 2023, Journal of the American College of Cardiology.
[15] I. Olivotto,et al. Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes , 2022, Journal of Medical Genetics.
[16] C. Wanner,et al. Patient reported quality of life and medication adherence in Fabry disease patients treated with migalastat: A prospective, multicenter study. , 2022, Molecular genetics and metabolism.
[17] Y. Chien,et al. Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: The 6-month primary analysis report. , 2022, Genetics in medicine : official journal of the American College of Medical Genetics.
[18] M. Wheeler,et al. Effect of beta‐blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy , 2022, European journal of heart failure.
[19] M. Gelb,et al. In Utero Enzyme-Replacement Therapy for Infantile-Onset Pompe's Disease. , 2022, The New England journal of medicine.
[20] P. DasMahapatra,et al. Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study. , 2022, Molecular genetics and metabolism.
[21] N. Smedira,et al. Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study , 2022, Circulation. Cardiovascular imaging.
[22] M. Desai,et al. Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks , 2022, Circulation.
[23] N. Reza,et al. Contemporary Therapies and Future Directions in the Management of Hypertrophic Cardiomyopathy , 2022, Cardiology and Therapy.
[24] B. Gersh,et al. Mavacamten Treatment for Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. , 2022, Current problems in cardiology.
[25] M. Russo,et al. Downregulation of Mannose-6-Phosphate Receptors in Fabry Disease Cardiomyopathy: A Potential Target for Enzyme Therapy Enhancement , 2022, Journal of clinical medicine.
[26] E. Prado Montes de Oca,et al. Prediction of Regulatory SNPs in Putative Minor Genes of the Neuro-Cardiovascular Variant in Fabry Reveals Insights into Autophagy/Apoptosis and Fibrosis , 2022, Biology.
[27] N. Smedira,et al. Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy. , 2022, Journal of the American College of Cardiology.
[28] A. Rodríguez-Gascón,et al. Galactomannan-Decorated Lipidic Nanocarrier for Gene Supplementation Therapy in Fabry Disease , 2022, Nanomaterials.
[29] C. Wanner,et al. Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study , 2022, Molecular genetics and metabolism reports.
[30] G. Donato,et al. Divergent Impact of Enzyme Replacement Therapy on Human Cardiomyocytes and Enterocytes Affected by Fabry Disease: Correlation with Mannose-6-phosphate Receptor Expression , 2022, Journal of clinical medicine.
[31] Wen-Chung Yu,et al. Left Ventricular Apical Aneurysm in Fabry Disease: Implications for Clinical Significance and Risk Stratification , 2022, Journal of the American Heart Association.
[32] F. Weidemann,et al. Chaperone Therapy in Fabry Disease , 2022, International journal of molecular sciences.
[33] D. Clark,et al. Copper chelation in patients with hypertrophic cardiomyopathy , 2022, Open Heart.
[34] M. Desai,et al. Management of hypertrophic cardiomyopathy. , 1993, Heart disease and stroke : a journal for primary care physicians.
[35] Hsiang-Yu Lin,et al. Fabry Disease and the Effectiveness of Enzyme Replacement Therapy (ERT) in Left Ventricular Hypertrophy (LVH) Improvement: A Review and Meta-Analysis , 2022, International journal of medical sciences.
[36] M. Tarnopolsky,et al. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial , 2021, The Lancet Neurology.
[37] B. Byrne,et al. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial , 2021, The Lancet Neurology.
[38] H. Zeng,et al. Case Report: A Novel LAMP2 Splice-Altering Mutation Causes Cardiac-Only Danon Disease , 2021, Frontiers in Cardiovascular Medicine.
[39] Emily A Eshraghian,et al. Abstract 10727: Results from First-in-Human Clinical Trial of RP-A501 (AAV9:LAMP2B) Gene Therapy Treatment for Danon Disease , 2021, Circulation.
[40] D. Rizopoulos,et al. Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium. , 2021, The Lancet. Child & adolescent health.
[41] Hong Qian,et al. Hypertrophic Cardiomyopathy: From Phenotype and Pathogenesis to Treatment , 2021, Frontiers in Cardiovascular Medicine.
[42] E. Chin,et al. Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy. , 2021, Journal of medicinal chemistry.
[43] B. Byrne,et al. Cardiac responses in paediatric Pompe disease in the ADVANCE patient cohort , 2021, Cardiology in the Young.
[44] P. Elliott,et al. Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy , 2021, European heart journal.
[45] E. Brand,et al. Precision medicine in Fabry disease. , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[46] T. Tsang,et al. Fabry Cardiomyopathy: Current Practice and Future Directions , 2021, Cells.
[47] D. Rader,et al. A genome-first approach to rare variants in hypertrophic cardiomyopathy genes MYBPC3 and MYH7 in a medical biobank , 2021, medRxiv.
[48] M. Weedon,et al. Prevalence of Fabry disease-causing variants in the UK Biobank , 2021, Journal of Medical Genetics.
[49] R. Bonow,et al. Fibrosis in Hypertrophic Cardiomyopathy Patients With and Without Sarcomere Gene Mutations. , 2021, Heart, lung & circulation.
[50] J. Spertus,et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial , 2021, The Lancet.
[51] Matthew W. Martinez,et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2021, The Journal of thoracic and cardiovascular surgery.
[52] N. Nadi,et al. Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: a systematic review and a meta-analysis , 2021, Journal of Neurology.
[53] C. Sommer,et al. Treatment of fabry disease with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS). , 2021, European heart journal. Cardiovascular pharmacotherapy.
[54] J. Medin,et al. Lentivirus-mediated gene therapy for Fabry disease , 2021, Nature Communications.
[55] B. Maron,et al. EVOLUTION OF RISK STRATIFICATION AND SUDDEN DEATH PREVENTION IN HYPERTROPHIC CARDIOMYOPATHY: 20 YEARS WITH THE IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR. , 2021, Heart rhythm.
[56] J. Corchero,et al. Nanotechnology-based approaches for treating lysosomal storage disorders, a focus on Fabry disease. , 2020, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[57] Yen-Hung Lin,et al. Long-term outcomes and left ventricular diastolic function of sarcomere mutation-positive and mutation-negative patients with hypertrophic cardiomyopathy: a prospective cohort study. , 2020, European heart journal cardiovascular Imaging.
[58] S. Solomon,et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial , 2020, The Lancet.
[59] N. Crawford,et al. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers , 2020, Clinical pharmacology in drug development.
[60] T. Kubo,et al. Lifelong Clinical Impact of the Presence of Sarcomere Gene Mutation in Japanese Patients With Hypertrophic Cardiomyopathy. , 2020, Circulation journal : official journal of the Japanese Circulation Society.
[61] R. Mamidi,et al. AAV9 gene transfer of cMyBPC N-terminal domains ameliorates cardiomyopathy in cMyBPC-deficient mice , 2020, JCI insight.
[62] S. S. St Martin,et al. AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction , 2020, Molecular therapy. Methods & clinical development.
[63] S. Solomon,et al. Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy. , 2020, Journal of the American College of Cardiology.
[64] F. Weidemann,et al. Diagnosis and Screening of Patients with Fabry Disease , 2020, Therapeutics and clinical risk management.
[65] N. Sousa,et al. Predictors of Fabry disease in patients with hypertrophic cardiomyopathy: How to guide the diagnostic strategy? , 2020, American heart journal.
[66] Yusu Gu,et al. Systemic AAV9.LAMP2B injection reverses metabolic and physiologic multiorgan dysfunction in a murine model of Danon disease , 2020, Science Translational Medicine.
[67] C. Wanner,et al. Cardiomyopathy and kidney function in agalsidase beta‐treated female Fabry patients: a pre‐treatment vs. post‐treatment analysis , 2020, ESC heart failure.
[68] M. Langeveld,et al. Developments in the treatment of Fabry disease , 2020, Journal of inherited metabolic disease.
[69] K. Nicholls,et al. Switching from agalsidase alfa to pegunigalsidase alfa for treating Fabry disease: One year of treatment data from BRIDGE, a phase III open label study , 2020 .
[70] D. Bali,et al. Improved muscle function in a phase I/II clinical trial of albuterol in Pompe disease. , 2019, Molecular genetics and metabolism.
[71] E. Fung,et al. Hypertrophic Cardiomyopathy: An Overview of Genetics and Management , 2019, Biomolecules.
[72] Chuan Liu,et al. A novel MYBPC3 c.2737+1 (IVS26) G>T mutation responsible for high-risk hypertrophic cardiomyopathy , 2019, Cardiology in the Young.
[73] C. Angelini,et al. Review: Danon disease: Review of natural history and recent advances , 2019, Neuropathology and applied neurobiology.
[74] D. Szczesna‐Cordary,et al. Therapeutic potential of AAV9-S15D-RLC gene delivery in humanized MYL2 mouse model of HCM , 2019, Journal of Molecular Medicine.
[75] P. Kellman,et al. Quantitative Myocardial Perfusion in Fabry Disease. , 2019, Circulation. Cardiovascular imaging.
[76] B. Greenberg,et al. Danon disease: Gender differences in presentation and outcomes. , 2019, International journal of cardiology.
[77] R. Schiffmann,et al. Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trial , 2019, Journal of inherited metabolic disease.
[78] Songtao Li,et al. Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction , 2019, Molecular therapy. Methods & clinical development.
[79] A. Owens,et al. Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy , 2019, Annals of Internal Medicine.
[80] C. Lukacs,et al. Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates. , 2019, American journal of human genetics.
[81] H. Deng,et al. Prevalence and clinical characteristics of Danon disease among patients with left ventricular hypertrophy and concomitant electrocardiographic preexcitation , 2019, Molecular genetics & genomic medicine.
[82] S. Tuske,et al. Improved efficacy of a next-generation ERT in murine Pompe disease. , 2019, JCI insight.
[83] M. Heartlein,et al. Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.
[84] B. Byrne,et al. Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascend , 2019, Neuromuscular Disorders.
[85] E. Belanger,et al. Lysosomal storage disorders affecting the heart: a review. , 2019, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.
[86] J. Oliveira,et al. The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts , 2019, Molecular genetics and metabolism reports.
[87] N. Sniadecki,et al. LAMP-2B regulates human cardiomyocyte function by mediating autophagosome–lysosome fusion , 2018, Proceedings of the National Academy of Sciences.
[88] Miguel Ángel Martínez,et al. The ACE I/D polymorphism does not explain heterogeneity of natural course and response to enzyme replacement therapy in Pompe disease , 2018, PloS one.
[89] S. Markova,et al. In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin , 2018, Xenobiotica; the fate of foreign compounds in biological systems.
[90] E. Ashley,et al. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy , 2018, Circulation.
[91] D. Corcoran,et al. Correction of Biochemical Abnormalities and Improved Muscle Function in a Phase I/II Clinical Trial of Clenbuterol in Pompe Disease. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.
[92] J. Seidman,et al. Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers , 2018, Proceedings of the National Academy of Sciences.
[93] E. Brand,et al. Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease. , 2018, Journal of the American Society of Nephrology : JASN.
[94] A. Kimura,et al. Genetic background of Japanese patients with pediatric hypertrophic and restrictive cardiomyopathy , 2018, Journal of Human Genetics.
[95] B. Bembi,et al. Diagnosis and treatment of the cardiovascular consequences of Fabry disease , 2018, QJM : monthly journal of the Association of Physicians.
[96] S. Cook,et al. Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center , 2018, Genetics in Medicine.
[97] F. Aarsen,et al. Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain , 2018, Developmental medicine and child neurology.
[98] B. Maron,et al. Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy. , 2018, JACC. Heart failure.
[99] C. Eng,et al. Fabry disease revisited: Management and treatment recommendations for adult patients. , 2018, Molecular genetics and metabolism.
[100] C. Wanner,et al. Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement , 2018, Clinical pharmacology and therapeutics.
[101] N. Chen,et al. Clinical significance of plasma globotriaosylsphingosine levels in Chinese patients with Fabry disease , 2018, Experimental and therapeutic medicine.
[102] B. Pau,et al. Efficient therapy for refractory Pompe disease by mannose 6‐phosphate analogue grafting on acid &agr;‐glucosidase , 2018, Journal of controlled release : official journal of the Controlled Release Society.
[103] M. Sabater-Molina,et al. Genetics of hypertrophic cardiomyopathy: A review of current state , 2018 .
[104] M. Kay,et al. Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase , 2017, Science Translational Medicine.
[105] E. Braunwald,et al. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. , 2017, Circulation research.
[106] Ajit S. Divakaruni,et al. Impaired mitophagy facilitates mitochondrial damage in Danon disease. , 2017, Journal of molecular and cellular cardiology.
[107] T. Driscoll,et al. Nonfamilial Hypertrophic Cardiomyopathy: Prevalence, Natural History, and Clinical Implications. , 2017, Circulation. Cardiovascular genetics.
[108] M. Amiri,et al. Case study on the pathophysiology of Fabry disease: abnormalities of cellular membranes can be reversed by substrate reduction in vitro , 2017, Bioscience reports.
[109] B. Byrne,et al. Inspiratory muscle conditioning exercise and diaphragm gene therapy in Pompe disease: Clinical evidence of respiratory plasticity , 2017, Experimental Neurology.
[110] Songtao Li,et al. Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction , 2017, Molecular therapy. Methods & clinical development.
[111] S. Cook,et al. Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes , 2017, European heart journal.
[112] S. Markova,et al. A Small Molecule Inhibitor of Sarcomere Contractility Acutely Relieves Left Ventricular Outflow Tract Obstruction in Feline Hypertrophic Cardiomyopathy , 2016, PloS one.
[113] D. Lockhart,et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study , 2016, Journal of Medical Genetics.
[114] Jian Wang,et al. Identification of LAMP2 Mutations in Early-Onset Danon Disease With Hypertrophic Cardiomyopathy by Targeted Next-Generation Sequencing. , 2016, The American journal of cardiology.
[115] D. Bruzzese,et al. Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: a systematic review and meta-analysis of the literature , 2016, Genetics in Medicine.
[116] D. Lockhart,et al. Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat. , 2016, The New England journal of medicine.
[117] B. Maron,et al. How Hypertrophic Cardiomyopathy Became a Contemporary Treatable Genetic Disease With Low Mortality: Shaped by 50 Years of Clinical Research and Practice. , 2016, JAMA cardiology.
[118] R. Boot,et al. Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases , 2016, FEBS letters.
[119] Christine E. Seidman,et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice , 2016, Science.
[120] A. T. van der Ploeg,et al. Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study , 2016, Journal of Inherited Metabolic Disease.
[121] T. Conlon,et al. Evaluation of Readministration of a Recombinant Adeno-Associated Virus Vector Expressing Acid Alpha-Glucosidase in Pompe Disease: Preclinical to Clinical Planning. , 2015, Human Gene Therapy Clinical Development.
[122] K. Frazer,et al. Brief Report: Oxidative Stress Mediates Cardiomyocyte Apoptosis in a Human Model of Danon Disease and Heart Failure , 2015, Stem cells.
[123] J. Seidman,et al. Phenotype and prognostic correlations of the converter region mutations affecting the β myosin heavy chain , 2015, Heart.
[124] B. Wang,et al. Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease , 2015, Molecular medicine.
[125] Barry J Maron,et al. New perspectives on the prevalence of hypertrophic cardiomyopathy. , 2015, Journal of the American College of Cardiology.
[126] M. Rudnicki,et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document , 2015, Orphanet Journal of Rare Diseases.
[127] B. Byrne,et al. Comparative impact of AAV and enzyme replacement therapy on respiratory and cardiac function in adult Pompe mice , 2015, Molecular therapy. Methods & clinical development.
[128] Matthew S. Lebo,et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity , 2015, Genetics in Medicine.
[129] C. Wanner,et al. The Fabry cardiomyopathy - diagnostic approach and current treatment. , 2014, Current pharmaceutical design.
[130] D. Sigg,et al. Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[131] Carmine Mollica,et al. A chaperone enhances blood α-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[132] M. Hubank,et al. Novel genotype–phenotype associations demonstrated by high-throughput sequencing in patients with hypertrophic cardiomyopathy , 2014, Heart.
[133] L. Mestroni,et al. Danon Disease: Clinical Features, Evaluation, and Management , 2014, Circulation: Heart Failure.
[134] Giuseppe Limongelli,et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). , 2014, European heart journal.
[135] Barry J Maron,et al. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. , 2014, Journal of the American College of Cardiology.
[136] D. Bali,et al. Adjunctive albuterol enhances the response to enzyme replacement therapy in late‐onset Pompe disease , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[137] M. Kroos,et al. Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease , 2014, Journal of Inherited Metabolic Disease.
[138] S. Luo,et al. Novel LAMP2 mutations in Chinese patients with Danon disease cause varying degrees of clinical severity. , 2014, Clinical neuropathology.
[139] B. Byrne,et al. Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[140] B. Byrne,et al. Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[141] T. Conlon,et al. Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes. , 2013, Human gene therapy.
[142] A. Pestronk,et al. Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. , 2012, Molecular genetics and metabolism.
[143] W. Mckenna,et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy: a proof of concept study , 2012 .
[144] Zhaoxia Wang,et al. Danon disease caused by two novel mutations of the LAMP2 gene: implications for two ends of the clinical spectrum. , 2012, Clinical neuropathology.
[145] C. Angelini,et al. Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years , 2012, Journal of Neurology.
[146] Songtao Li,et al. β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease. , 2012, Molecular genetics and metabolism.
[147] P. Elliott,et al. Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[148] Yuan-Tsong Chen,et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease , 2011, Genetics in Medicine.
[149] Songtao Li,et al. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle. , 2011, Molecular genetics and metabolism.
[150] Matthew R. G. Taylor,et al. Natural history of Danon disease , 2011, Genetics in Medicine.
[151] H. Fu,et al. Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[152] Carolyn Y. Ho,et al. Is Genotype Clinically Useful in Predicting Prognosis in Hypertrophic Cardiomyopathy? Genetics and Clinical Destiny: Improving Care in Hypertrophic Cardiomyopathy Response by Landstrom on P 2440 Genetics of Hcm Controversies in Cardiovascular Medicine , 2022 .
[153] J. Jaeken,et al. Effect of enzyme therapy in juvenile patients with Pompe disease: A three-year open-label study , 2010, Neuromuscular Disorders.
[154] Matthew R. G. Taylor,et al. Functional performance and muscle strength phenotypes in men and women with Danon disease , 2010, Muscle & nerve.
[155] D. Germain. Fabry disease , 2010, Orphanet journal of rare diseases.
[156] R. Hopkin,et al. Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: Findings from the Fabry Registry , 2010, Genetics in Medicine.
[157] J. E. Wraith,et al. Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience , 2010, Journal of Inherited Metabolic Disease.
[158] B. Bembi,et al. Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II , 2010, Journal of Inherited Metabolic Disease.
[159] A. Pestronk,et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. , 2010, The New England journal of medicine.
[160] Michael J Ackerman,et al. Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. , 2010, Journal of the American College of Cardiology.
[161] B. Wong,et al. LAMP2 Microdeletions in Patients With Danon Disease , 2010, Circulation. Cardiovascular genetics.
[162] Y. Chien,et al. Genetic heterozygosity and pseudodeficiency in the Pompe disease newborn screening pilot program. , 2010, Molecular genetics and metabolism.
[163] T. Conlon,et al. Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[164] G. Bonsel,et al. Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers. , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[165] M. Kulis,et al. Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[166] J. Clancy,et al. Early Treatment With Alglucosidase Alfa Prolongs Long-Term Survival of Infants With Pompe Disease , 2009, Pediatric Research.
[167] F. Endo,et al. High frequency of acid alpha-glucosidase pseudodeficiency complicates newborn screening for glycogen storage disease type II in the Japanese population. , 2009, Molecular genetics and metabolism.
[168] R. Mattaliano,et al. Glycoengineered Acid α-Glucosidase With Improved Efficacy at Correcting the Metabolic Aberrations and Motor Function Deficits in a Mouse Model of Pompe Disease. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[169] B. Maron,et al. Sudden Deaths in Young Competitive Athletes: Analysis of 1866 Deaths in the United States, 1980–2006 , 2009, Circulation.
[170] D. Szczesna‐Cordary,et al. Malignant familial hypertrophic cardiomyopathy D166V mutation in the ventricular myosin regulatory light chain causes profound effects in skinned and intact papillary muscle fibers from transgenic mice , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[171] B. Byrne,et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease , 2009, Genetics in Medicine.
[172] M. Beer,et al. Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy Evidence for a Better Outcome With Early Treatment , 2009 .
[173] M. Regnier,et al. Contribution of the Myosin Binding Protein C Motif to Functional Effects in Permeabilized Rat Trabeculae , 2008, The Journal of general physiology.
[174] R. Hopkin,et al. Fabry's disease , 2008, The Lancet.
[175] A. Pestronk,et al. Clinical features of late‐onset Pompe disease: A prospective cohort study , 2008, Muscle & nerve.
[176] Peter Nürnberg,et al. Beyond the sarcomere: CSRP3 mutations cause hypertrophic cardiomyopathy. , 2008, Human molecular genetics.
[177] E. Génin,et al. Identifying modifier genes of monogenic disease: strategies and difficulties , 2008, Human Genetics.
[178] E. Aronica,et al. EXTENSION OF THE CLINICAL SPECTRUM OF DANON DISEASE , 2008, Neurology.
[179] R. Brady,et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease , 2008, Proceedings of the National Academy of Sciences.
[180] C. Tei,et al. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. , 2008, Journal of cardiology.
[181] M. Yacoub,et al. 'End-stage' hypertrophic cardiomyopathy: from mystery to model , 2007, Nature Clinical Practice Cardiovascular Medicine.
[182] P. Elliott,et al. The heart in Anderson-Fabry disease and other lysosomal storage disorders , 2007, Heart.
[183] B. Byrne,et al. Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[184] W. Hwu,et al. Recombinant human acid α-glucosidase: Major clinical benefits in infantile-onset Pompe disease , 2007 .
[185] Wuh-Liang Hwu,et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. , 2006, The Journal of pediatrics.
[186] J. Towbin,et al. Danon Disease as an Underrecognized Cause of Hypertrophic Cardiomyopathy in Children , 2005, Circulation.
[187] I. Nishino,et al. Asymptomatic hyperCKemia in a case of Danon disease due to a missense mutation in Lamp-2 gene , 2005, Neuromuscular Disorders.
[188] D. Koeberl,et al. Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[189] J. Sandstede,et al. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. , 2005, European heart journal.
[190] R. Moss,et al. Binding of Myosin Binding Protein-C to Myosin Subfragment S2 Affects Contractility Independent of a Tether Mechanism , 2004, Circulation research.
[191] M. Komajda,et al. Calcified mediastinal haematoma: a rare case of cardiac constriction , 2004, Heart.
[192] D. Pennell,et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. , 2003, European heart journal.
[193] P. Elliott,et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. , 2003, Journal of the American College of Cardiology.
[194] W. Hop,et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. , 2003, Pediatrics.
[195] Ferhaan Ahmad,et al. Transgenic Mice Overexpressing Mutant PRKAG2 Define the Cause of Wolff-Parkinson-White Syndrome in Glycogen Storage Cardiomyopathy , 2003, Circulation.
[196] S. Kornfeld,et al. Mannose 6-phosphate receptors: new twists in the tale , 2003, Nature Reviews Molecular Cell Biology.
[197] B. Byrne,et al. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[198] C. Eng,et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. , 2001, The New England journal of medicine.
[199] S. Dimauro,et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease) , 2000, Nature.
[200] F. Martiniuk,et al. Identification of two subtypes of infantile acid maltase deficiency. , 2000, The Journal of pediatrics.
[201] N. Raben,et al. Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[202] D. Pauly,et al. Complete correction of acid α-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle , 1998, Gene Therapy.
[203] N. Raben,et al. A model of mRNA splicing in adult lysosomal storage disease (glycogenosis type II). , 1996, Human molecular genetics.
[204] J. Gardin,et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. , 1995, Circulation.
[205] C. Boerkoel,et al. Leaky splicing mutation in the acid maltase gene is associated with delayed onset of glycogenosis type II. , 1995, American journal of human genetics.
[206] S. Dimauro,et al. Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (-13T-->G) mutation in a majority of patients and a novel IVS10 (+1GT-->CT) mutation. , 1994, Human molecular genetics.
[207] L. Hoefsloot,et al. Characterization of the human lysosomal alpha-glucosidase gene. , 1990, The Biochemical journal.
[208] S. Dimauro,et al. Lysosomal glycogen storage disease with normal acid maltase , 1981, Neurology.
[209] J. Moller,et al. Electrocardiographic and vectorcardiographic abnormalities in Fabry's disease. , 1977, American heart journal.
[210] C. Semsarian,et al. Making The Case For Cascade Screening Amongst Families With Inherited Heart Diseases. , 2019, Heart rhythm.
[211] C. Rapezzi,et al. The Electrocardiogram in the Diagnosis and Management of Patients with Hypertrophic Cardiomyopathy. , 2019, Heart rhythm.
[212] Thomas P. Mechtler,et al. Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes. , 2017, Molecular genetics and metabolism.
[213] T. Conlon,et al. Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in Children Affected by Pompe Disease. , 2017, Human gene therapy. Clinical development.
[214] M. Namdar. Electrocardiographic Changes and Arrhythmia in Fabry Disease , 2016, Front. Cardiovasc. Med..
[215] N. Karabul,et al. Outcome of patients with classical infantile pompe disease receiving enzyme replacement therapy in Germany. , 2015, JIMD reports.
[216] T. Conlon,et al. Phase I / II Trial of Diaphragm Delivery of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase ( rAAV 1-CMV-GAA ) Gene Vector in Patients with Pompe Disease , 2014 .
[217] B. Bembi,et al. The angiotensin-converting enzyme insertion/deletion polymorphism modifies the clinical outcome in patients with Pompe disease , 2010, Genetics in Medicine.
[218] F. Glocker,et al. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial , 2009, Journal of Neurology.
[219] D. Germain,et al. Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies. , 2009, International journal of clinical pharmacology and therapeutics.
[220] Germain Dp,et al. Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies. , 2009 .
[221] R. Mattaliano,et al. Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[222] 寺口 博幸. Terminal stage cardiac findings in patients with cardiac Fabry disease : an electrocardiographic, echocardiographic, and autopsy study , 2008 .
[223] B. Byrne,et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. , 2007, Neurology.